Key result
Monitoring troponin, pro-brain natriuretic peptide, and other cardiac biomarkers during chemotherapy helps to early detect cardiotoxicity and prevent irreversible cardiovascular outcomes.
Why the study?
Chemotherapy is linked to increased risk of cardiotoxicity and heart failure, making early detection crucial to prevent life-threatening and irreversible cardiovascular outcomes.
Does monitoring cardiac biomarkers help in the early detection of cardiotoxicity in patients receiving chemotherapy?
Does monitoring cardiac biomarkers help in the early detection of cardiotoxicity in patients receiving chemotherapy?
This review emphasizes the importance of incorporating cardiac biomarkers like troponin and pro-BNP alongside echocardiography for the early detection and management of chemotherapy-induced cardiotoxicity.
May warrant biomarker monitoring in chemotherapy patients; leaves open randomized confirmation of outcome benefit.
PURPOSE: This review aims to highlight the different types of chemotherapy-induced cardiotoxicity and will discuss the evidence base behind the use of different cardiac biomarkers to predict cardiovascular complications. Additionally, we will review the use of cardiac biomarkers to monitor cardiac outcomes and the role of cardioprotective medications in reducing cardiovascular side effects. RECENT FINDINGS: Chemotherapy has been linked to an increased risk of cardiotoxicity and heart failure. Currently, patients receiving chemotherapy undergo echocardiogram before starting chemotherapy and every 6 months to monitor for any decline in cardiac function. We reviewed the current evidence and practice guidelines of monitoring chemotherapy cardiotoxicity. SUMMARY: Cardio-oncology is a rapidly evolving subspecialty in cardiology, especially with the advent of new chemotherapeutic agents, which have cardiovascular side effects. Early detection of these effects is crucial to prevent life-threatening and irreversible cardiovascular outcomes. Monitoring troponin, pro-brain natriuretic peptide, and other cardiac biomarkers during chemotherapy will help to early detect cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Battisha et al. (2023) conducted a review in Chemotherapy-induced cardiotoxicity. Cardiac biomarkers (troponin, pro-brain natriuretic peptide) was evaluated. Monitoring troponin, pro-brain natriuretic peptide, and other cardiac biomarkers during chemotherapy helps to early detect cardiotoxicity and prevent irreversible cardiovascular outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: